CD274 and non-small cell lung carcinoma: Tissue-based programmed cell death-ligand 1 (PD‐L1) expression is the main criterion for the prediction of ICI treatment and has been shown to correlate with the efficacy of PD‐1/PD‐L1 blockade therapy in NSCLC (6, 7).